ARTICLE SUMMARY:
The US market for drug-coated balloons used to treat peripheral arterial disease is expected to ramp up quickly in the coming year, igniting a fierce battle for market share between CR Bard, with FDA approval already in hand, and Medtronic, which is awaiting approval. While these two fight it out for dominance in the US, the largest prize in a potential $1 billion-plus worldwide opportunity, others are queuing up as well, including Spectranetics.
The US peripheral arterial disease (PAD) device market, which has been outperforming the coronary interventional field in terms of growth for the past several years, is about to get even more interesting with the recent FDA PMA approval of CR Bard Inc.’s Lutonix drug-coated balloon (DCB).
